Pure Global AI
NCT06329206Recruiting

A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors

A Phase Ia/Ib, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GH2616 Tablet in Subjects With Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
GH2616 Tablets
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Suzhou Genhouse Bio Co., Ltd.
Location
Zhejiang, China
Timeline & enrollment
Phase
Phase 1
Start date
Mar 20, 2024
End date
Sep 01, 2026
Enrollment
156 participants
Primary outcome

Safety assessment

Summary

This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety,
 tolerability, PK, pharmacodynamics (PD) and preliminary efficacy of GH2616 Tablet in subjects
 with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and
 the dose expansion study (Phase Ib).

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06329206
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06329206 through Pure Global AI's free database. This Phase 1 trial is sponsored by Suzhou Genhouse Bio Co., Ltd. and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 156 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.